There's A Lot To Like About Cencora's (NYSE:COR) Upcoming US$0.51 Dividend

19h ago, source:

Readers hoping to buy Cencora, Inc. ( NYSE:COR ) for its dividend will need to make their move shortly, as the stock ...

Cencora Outperforms in Q2: A Buy Rating with Room to Grow

2d ago, source:

Bank of America Securities analyst Allen Lutz has reiterated their bullish stance on COR stock, giving a Buy rating today. Allen Lutz has ...

Cencora, Inc. to Announce Second Quarter Fiscal 2024 Results on May 1

25d ago, source: MyChesCo on MSN

CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) is set to release its financial results for the second quarter of fiscal year ...

Cencora Inc ABG

23d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Unveiling 4 Analyst Insights On Cencora

2d ago, source: Business Insider

Throughout the last three months, 4 analysts have evaluated Cencora (NYSE:COR), offering a diverse set of opinions from ...

Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release

29d ago, source: Stockhouse

Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening of trading on the New York Stock ...

3 Stocks to Watch in the Drug Distribution Industry

5d ago, source: Morningstar

Taken together, Cardinal Health, Cencora, and McKesson make up 95% of the overall US ... a wholly owned subsidiary of ...

Insider Sell: Cencora Inc (COR) Chairman, President & CEO Steven Collis Sells 10,754 Shares

17d ago, source:

Steven Collis, Chairman, President & CEO of Cencora Inc (NYSE:COR), sold 10,754 shares of the company on April 16, 2024, ...

Cencora beats profit estimates on strong demand for costly specialty drugs

3d ago, source:

Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis.